(Rac) -Salvianic acid A

(Rac) -Salvianic acid A is the racemate of Salvianic acid A (HY-N1913) . Salvianic acid A, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

Product Specifications

CAS Number

[23028-17-3]

Product Name Alternative

(Rac) -Danshensu; (Rac) -Tanshinol

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Drug Isomer

Type

Natural Products

Related Pathways

Others

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/rac-salvianic-acid-a.html

Solubility

10 mM in DMSO

Smiles

O=C(C(CC1=CC=C(C(O)=C1)O)O)O

Molecular Formula

C9H10O5

Molecular Weight

198.17

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43 (4) :771-780. |[2]V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne) . 2020 Sep 30:11:568436. |[3]Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995.